Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Glioma × ulixertinib × Clear all

Phase

Phase 2 2 Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Magnetic Resonance Spectroscopy 7 fluciclovine F-18 4 Temozolomide 4 Radiotherapy 4 fluorodopa F 18 3 Topotecan 3 niraparib 2 abemaciclib 2 Standard of Care 2 Specimen Handling 2 Pemetrexed 2 Ketoconazole 2 Biopsy 2 ulixertinib 1 temsirolimus 1 ribociclib 1 posaconazole 1 poly ICLC 1 pembrolizumab 1 orludodstat 1 lorlatinib 1 larotrectinib 1 infigratinib 1 fisetin 1 fimepinostat 1 evolocumab 1 clevudine 1 X-Rays 1 Watchful Waiting 1 Vardenafil Dihydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05804227 2026-02-27

Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Recruiting

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡